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Potential Role of Tumor Necrosis Factor-a in
Downregulating Sex Hormone–Binding Globulin
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Low plasma sex hormone–binding globulin (SHBG) levels are as-
sociated with obesity and predict the development of type 2 di-
abetes. The reason why obese individuals have low circulating
SHBG has been attributed to hyperinsulinemia, but no mechanis-
tic evidence has been described. The aim of the current study is
to explore whether tumor necrosis factor-a (TNF-a) rather than
insulin could be the main factor accounting for low SHBG levels
in obesity. We performed in vitro and in vivo studies using human
HepG2 cells and human SHBG transgenic mice. In addition,
a cross-sectional study to explore the relationship between
TNF-a and SHBG in obese patients and an interventional study
to examine the effect of insulin administration on circulating
SHBG in type 2 diabetic patients were performed. We provide
evidence that TNF-a, but not insulin, is the main factor by which
SHBG is reduced in obesity. Plasma SHBG was significantly in-
creased rather than decreased after insulin treatment in diabetic
patients. TNF-a–induced reduction of SHBG expression was me-
diated by downregulating HNF4A. Finally, a negative and inde-
pendent correlation was found between plasma TNF-a receptor 1
and SHBG levels in obese patients. Our results suggest that TNF-
a plays an important role downregulating SHBG in chronic
low-grade inflammatory diseases such as obesity and type 2
diabetes. Diabetes 61:372–382, 2012
S
ex hormone–binding globulin (SHBG) is produced
and secreted by the human liver, and it binds an-
drogens and estrogens with high affinity. In blood,
SHBG acts as a carrier of these sex steroids and
regulates their bioavailability (1). Low plasma SHBG levels
are associated with obesity, abdominal adiposity, and met-
abolic syndrome and predict the development of type 2
diabetes (2–4). In addition, an inverse relationship between
plasma SHBG levels and risk of cardiovascular disease has
been reported (5,6).
BMI is considered a major determinant of SHBG plasma
concentrations (7,8). Obese individuals of all ages have
low plasma SHBG levels (7,8). Although low plasma SHBG
levels in obese individuals have been attributed to hyper-
insulinemia (9,10), we have recently demonstrated that
excessive intake of monosaccharides leads to lower human
SHBG production by the liver by reducing hepatocyte
nuclear factor 4-a (HNF4-a) (11), a key transcription
factor that regulates SHBG expression in the liver (12). In
addition, it has been reported that low concentrations of
SHBG are strongly associated with increased risk of de-
veloping metabolic syndrome independently of insulin re-
sistance (2). Furthermore, Peter et al. (13) have recently
shown that SHBG is not related to fasting insulinemia or
insulin secretion. All these findings suggest that other
mechanisms unrelated to insulin signaling pathways should
be involved in the low levels of plasma SHBG observed in
obesity.
Accumulating evidence over the past decade points to
inflammation as one of the critical processes associated
with the development of obesity, insulin resistance, and
diabetes (14,15). In fact, obesity is considered a state of
chronic low-grade inflammation (16). A robust inverse cor-
relation has recently been found between testosterone
and SHBG levels with C-reactive protein levels (17). The
authors suggested a potential role of androgens in inflam-
matory processes, but owing to the cross-sectional nature of
the study, the alternative hypothesis that low testosterone
and SHBG could be a consequence of inflammation should
not be ruled out (17). The proinflammatory cytokine tumor
necrosis factor-a (TNF-a) is elevated in obese patients (18)
and in other inflammatory diseases (19,20). In obese sub-
jects, TNF-a is mainly produced by macrophages that in-
filtrate the expanded adipose tissue, and its levels correlate
to the degree of adiposity and insulin resistance (21). Evi-
dence for a key role of TNF-a in obesity-related insulin re-
sistance comes from studies showing that deletion of TNF-a
or TNF-a receptors (TNF-a-Rs) results in significantly im-
proved insulin sensitivity in both diet-induced obese mice
and leptin-deficient ob/ob mice (22,23). TNF-a signals
through two cell-surface receptors, TNF-a-R1 and TNF-a-R2,
and membranous shedding of these receptors reflects acti-
vation of the TNF system (24,25). In fact, increased plasma
levels of TNF-a-Rs are found in obese individuals (25). The
half-life of TNF-a is only 4.6 min, and its circulating levels
are highly variable (26). By contrast, soluble (s)TNF-a-Rs
are more stable proteins, remaining elevated in systemic cir-
culation for longer periods of time and, therefore, are better
markers for the activation of the TNF-a system than TNF-a
itself (27).The TNF-a actions in the liver mainly occur
through TNF-a-R1 (28), and they are mediated by nuclear
factor-kB (NF-kB), Jun NH2-terminal kinase, and p38 ki-
nase (29).
Given that an inverse relationship has been reported
between TNF-a and SHBG plasma levels in several chronic
inflammatory diseases (19,20), it is plausible that TNF-a
could be the reason for low plasma SHBG levels that exist
in obesity. However, to the best of our knowledge, this hy-
pothesis has never been tested. To shed light on this issue,
we have addressed the question of whether human SHBG
expression in the liver is regulated by TNF-a and/or insulin
and which signaling pathways are involved. For these pur-
poses, we have performed in vitro studies using human
HepG2 hepatoblastoma cells, as well as in vivo studies using
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human SHBG transgenic mice that harbor the complete
transcription unit responsible for human SHBG production
by hepatocytes. This is the only mouse model available to
study SHBG expression in vivo because adult mice do not
express SHBG in their livers. Finally, we have performed
two studies in humans, one addressed to investigating the
effect of insulin administration on serum SHBG levels in
type 2 diabetic patients and the other to assessing whether
measurements of TNF-a-R1 are independently related to
plasma SHBG levels in obese patients.
RESEARCH DESIGN AND METHODS
Subjects and samples
Interventional study: insulin administration in type 2 diabetic patients.
Serum samples from 20 consecutive type 2 diabetic men who failed to respond
to oral antidiabetes agents and who were admitted to the hospital to initiate
treatment with insulin were selected. These patients were hepatitis C virus (HCV)
negative, had a C-peptide ,1.2 ng/mL (0.5 6 0.48) (thus providing an insulino-
penic state), and in all cases, hepatic steatosis was excluded by ultrasonography.
During admission, they received the same type of diet (carbohydrates
constituted 55% of total caloric content). In all cases, patients were treated with
both long-acting insulin (0.4 UI/kg/day) and short-acting insulin administered
before breakfast, lunch, and dinner (0.1, 0.15, and 0.15 UI/kg, respectively).
Total daily insulin dose was adjusted every day according with the values from
the nine-point glucose profile obtained the day before. After 7–10 days of in-
sulin treatment (insulin dose mean: 60 6 24 UI/day), another serum sample
was drawn. The following parameters were compared before and after insu-
linization: BMI, glucose, fructosamine, HbA1c, total cholesterol, triglycerides,
sTNF-a-R1, and SHBG.
Cross-sectional study. We recruited 97 consecutive obese subjects (BMI
44.9 6 6.3 kg/m2; waist circumference .102 cm in men and.88 cm in women)
of Caucasian origin attended in the University Hospital Vall d’Hebron Obesity
Unit. Approximately half of the recruited subjects (46.3%) were taking anti-
hypertensive medications, and 18.5% were taking lipid-lowering drugs.
Exclusion criteria were 1) diabetic patients; 2) history of cardiovascular
disease; 3) treatment with estrogens, androgens, corticosteroids, antibiotics,
or anti-inflammatory agents; and 4) hospitalization in the preceding 2 months.
Diabetes was defined on the basis of a history of therapy with oral hypo-
glycemic agents or insulin at the time of inclusion. In all patients not previously
diagnosed, the criteria recommended by the Expert Committee on the Di-
agnosis and Classification of Diabetes were used (30). Thus, diabetes was
diagnosed if the fasting blood glucose was $7 mmol/L (126 mg/dL) on two
separate occasions, and impaired fasting glucose (IFG) was diagnosed if the
fasting blood glucose was between 5.6 mmol/L (100 mg/dL) and 6.9 mmol/L
(125 mg/dL).
Informed written consent was obtained from all participants, and the study
was approved by the human ethics committee from the Hospital Vall d’Hebron.
Serum analysis. All laboratory measurements were performed on fasting
blood samples. Serum glucose, fasting insulin, fructosamine, HbA1c, total cho-
lesterol, and triglycerides were measured by standard laboratory techniques
used in clinical chemistry laboratories. Insulin resistance was determined by the
homeostasis model assessment (HOMA-IR).
SHBG and TNF-a-R1 were determined by enzyme-linked immunosorbent
assay (ELISA; Demeditec Diagnostics GmbH, Kiel-Wellsee, Germany, and Leti
Diagnostics, Badalona, Spain).
Animals. Mice C57BL6 expressing human SHBG transgenes have been char-
acterized previously (12). Mice were maintained under standard conditions with
food (Global Diet 2018; Harlan Interfauna Iberica, Barcelona, Spain) and water
provided ad libitum and a 12-h light/dark cycle. Experimental procedures were
approved by the institutional animal use subcommittees of Hospital Vall
d’Hebron Research Institute and the Universitat Autònoma Barcelona.
In vivo experiments. Male mice were treated with daily intraperitoneal
injections of phosphate-buffered saline (PBS), 5 mg TNF-a (Miltenyi Biotech
S.L., Madrid, Spain), or 5 mg TNF-a and 1 mg NF-kB inhibitor QNZ (Enzo Life
Sciences International, Inc., Plymouth Meeting, PA) for 5 days. Blood samples
were taken by saphenous vein for measurements of plasma SHBG levels im-
mediately before the treatment and on days 3 and 5 when livers were taken for
RNA and protein extraction. Treatments did not affect animal weight.
Cell culture experiments. Cell culture reagents were from Life Technologies
Inc. (Invitrogen SA, Barcelona, Spain). HepG2 hepatoblastoma cells (catalog no.
HB-8065; American Type Culture Collection) were maintained in Dulbecco’s
modified Eagle’s medium supplemented with 10% FBS and antibiotics. For
experiments, HepG2 cells were cultured to 50–70% confluence prior to the
addition of vehicle (PBS or DMSO), TNF-a (Miltenyi Biotech S.L.), insulin
(Sigma-Aldrich, Madrid, Spain), SP600125 (Sigma-Aldrich), and SB203580
(Sigma-Aldrich).
Stable transfections with the HNF4A expression vector were performed
using Lipofectamine 2000 (Invitrogen SA) and G418 (Invitrogen SA).
SHBG measurements. Human SHBG levels in culture medium taken from
HepG2 cells or from mice plasma were measured using an ELISA (Demeditec
Diagnostics GmbH).
ELISAs. Plasma soluble TNF-a-R1 levels were measured using Quantikine
Immunoassay (MRT10; R&D Systems Europe, Ltd., Abingdon, U.K.).
RNA analysis. Total RNA was extracted from HepG2 cells and mice livers
using TRIzol reagent (Invitrogen SA). Reverse transcription was performed at
42°C for 50 min using 3 mg of total RNA and 200 units of Superscript II to-
gether with an oligo-dT primer and reagents provided by Invitrogen. An aliquot
of the reverse-transcription product was amplified in a 25-mL reaction using
SYBRGreen (Invitrogen SA) with appropriate oligonucleotide primer pairs
corresponding to human HNF4-a, mouse HNF4-a, human SHBG, human 18S,
and mouse 18S (Supplementary Table 1). Results were analyzed using the 7000
SDS program (Applied Biosystems).
Western blot analysis. After treatments, mouse livers or HepG2 cells were
homogenized in radioimmunoprecipitation assay buffer with Complete pro-
tease inhibitor cocktail (Roche Diagnostics, Barcelona, Spain). Protein extracts
were used for Western blotting with antibodies against human HNF4-a (C-19;
catalog sc-6556; Santa Cruz Biotechnology Inc., Heidelberg, Germany), human
phospho–NF-kB (sc-33039; Santa Cruz Biotechnology Inc.), phospho–IRS-1
(insulin receptor substrate 1) (sc-101712; Santa Cruz Biotechnology Inc.),
phospho-S6 ribosomal protein (catalog 2211; Cell Signaling Technology Inc.),
and human PPIA (SA-296; BIOMOL Int., Madrid, Spain). Specific antibody-
antigen complexes were identified using a horseradish peroxidase–labeled
goat anti-rabbit IgG or rabbit anti-goat IgG and chemiluminescent substrates
(Pierce Biotechnology Inc., Barcelona, Spain) by exposure to X-ray film.
Chromatin immunoprecipitation assays. After treatment, HepG2 cells and
mice livers were used to perform chromatin immunoprecipitation (ChIP) as-
says with a ChIP-IT kit (Active Motif Inc.) as described previously (11). The
purified DNA was subjected to PCR amplification using specific primers de-
signed to amplify a 306–base pair of the human SHBG promoter.
Statistical analyses. Normal distribution of the variables was evaluated using
the Kolmogorov-Smirnov test. Comparison of quantitative variables was per-
formed by either Student t test or Mann-Whitney U test according to the data
distribution. All data are presented as means 6 SD or medians [range].
Spearman correlation coefficients were used to establish the association be-
tween SHBG levels and the other parameters. For graphics, a linear regression
test was applied.
Stepwise multiple regression analysis was performed to explore the vari-
ables independently related to SHBG levels. The variables that significantly
correlated with SHBG levels in univariate analysis and those with clinical
relevance (i.e., age and BMI) were included as independent variables in
multivariate analysis. All P values were based on a two-sided test of statisti-
cal significance. Significance was accepted at the level of P , 0.05. Statis-
tical analyses were performed with the SPSS statistical package (SPSS Inc,
Chicago, IL).
RESULTS
TNF-a decreases SHBG production by HepG2 cells,
whereas insulin does not. We first examined the ef-
fects of daily supplementation of different doses of insulin
(0, 20, 100, or 200 mU/mL) or TNF-a (0, 50, 100, or 200 ng/mL)
on SHBG production by HepG2 cells over the course of
5 days. This was done by comparing medium concen-
trations of SHBG on days 1 and 5 of vehicle and different
doses of insulin or TNF-a. As expected, insulin treatment
induced an increase in phosphorylation of IRS-1 and PS6
proteins (Fig. 1A). However, the different concentrations
of insulin did not change SHBG protein levels (Fig. 1B) or
SHBG mRNA levels (Fig. 1C). By contrast, TNF-a treat-
ments reduced SHBG production (Fig. 1D) and SHBG
mRNA levels (Fig. 1E) in HepG2 cells.
We next studied the daily supplementation with TNF-a
on SHBG production by HepG2 cells grown in the pres-
ence or absence of insulin over the course of 5 days. These
treatments showed that cells treated with TNF-a with or
without insulin had a reduced SHBG production (P, 0.01)
when compared with vehicle- or insulin alone–treated cells
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FIG. 1. Daily treatment with TNF-a, but not insulin, decreases SHBG production over 5 days in HepG2 cells. A: HepG2 cells were treated daily with
vehicle and different doses of insulin for 5 days. P-IRS-1 and P-S6 protein levels were measured by Western blotting using PPIA as a housekeeping
reference protein in HepG2 cells. B: SHBG accumulation in the medium was measured using an ELISA in HepG2 cells treated as in (A). Data points are
mean 6 SD of triplicate measurements. C: Analysis of SHBG mRNA levels in HepG2 cells treated as in (A). Human 18S mRNA was amplified as
a control. Data points are shown as mean 6 SD of triplicates. D: HepG2 cells were treated daily with vehicle and different doses of TNF-a for 5 days.
SHBG accumulation in the medium was measured using an ELISA. E: Analysis of SHBG mRNA levels in HepG2 cells treated as in (D). Human 18S
mRNA was amplified as a control. Data points are shown as mean 6 SD of triplicates. F: HepG2 cells were treated daily with vehicle, insulin, TNF-a, or
TNF-a plus insulin for 5 days. SHBG accumulation in the medium was measured using an ELISA. G: Analysis of SHBG mRNA levels in HepG2 cells
treated as in (F). Human 18SmRNAwas amplified as a control. Data points are shown asmean6 SD of triplicates. **P< 0.01 compared with the control.
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(Fig. 1F). In addition, the amount of SHBG mRNA in
HepG2 cells after 5 days of treatment with TNF-a with or
without insulin was significantly (P , 0.01) decreased in
relation to the 18S mRNA control when compared with
vehicle- or insulin alone–treated cells (Fig. 1G).
Finally, it should be noted that TNF-a treatment for 5 days
did not affect the viability or survival of the HepG2 cells
when compared with vehicle-treated cells assessed by
transferase-mediated dUTP nick-end labeling assays
(Supplementary Fig. 1).
Insulin administration does not downregulate SHBG
production in type 2 diabetic patients. To confirm that
insulin does not play an essential role in reducing SHBG
production, we conducted an interventional study in type 2
diabetic patients requiring insulin treatment. For this pur-
pose, we collected serum samples from 20 consecutive
type 2 diabetic men who had failed to respond to oral
antidiabetes agents before and after 7–10 days of initiating
insulin treatment. The SHBG significantly increased rather
than decreased after insulin treatment (Table 1). In addi-
tion, a correlation between the decrease of blood glucose
levels and the increase of SHBG was found (r = 0.59; P =
0.019). Apart from demonstrating that insulin does not
downregulate SHBG production, we examined the effect of
insulin administration on sTNF-a-R1 and its relationship
with SHBG. As shown in Table 1, a significant reduction of
sTNF-a-R1 was detected after insulin treatment (1.466 0.96
vs. 0.88 6 0.77 ng/mL; P = 0.003), and the decrease was
observed in 17 of 20 cases. Finally, it should be stressed that
BMI was very similar at patient admission and discharge,
thus ruling out this variable as a confounding factor.
TNF-a influences hepatic SHBG production indirectly
by decreasing HNF4-a levels through activation of
NF-kB. Given that HNF4-a plays a key role in the tran-
scriptional activity of the human SHBG promoter (12), we
examined HNF4-a protein levels in HepG2 cells after 5
days of treatment with vehicle or insulin, TNF-a, and TNF-
a/insulin. These treatments showed that cells treated with
TNF-a with or without insulin had reduced HNF4-a protein
levels (P , 0.01) when compared with vehicle- or insulin
alone–treated cells (Fig. 2A).
To study by which signaling pathway TNF-a was re-
ducing SHBG expression, we treated HepG2 cells with
QNZ (10 nmol/L to 1 mmol/L), SP600125 (500 nmol/L), and
SB203580 (500 nmol/L), which are inhibitors of NF-kB, Jun
NH2-terminal kinase, and p38, respectively. After 5 days of
treatment with QNZ, the HepG2 cells died (data not
shown). Treatments with the other inhibitors did not
influence or block the reduction in SHBG production after
cotreatment with TNF-a (50 ng/mL) in HepG2 (Fig. 2B),
although they inhibited phosphorylation of p38 or c-Jun
induced by the TNF-a treatment (Supplementary Fig. 2).
Moreover, HNF4-a protein levels were also reduced
when HepG2 cells were treated with TNF-a (50 ng/mL)
in the presence of SP600125 (500 nmol/L) or SB203580
(500 nmol/L) when compared with the vehicle and of
SP600125 (500 nmol/L) or SB203580 (500 nmol/L) alone
(Fig. 2C).
We next explored the possibility of preventing TNF-a–
induced downregulation of SHBG by stably transfecting
an HNF4-a expression vector. HNF4-a overexpression
in TNF-a–treated cells increased SHBG production and
SHBG mRNA levels to the levels of untreated HepG2 cells
transfected with an empty vector (EV) (Fig. 2D and E).
Furthermore, HNF4-a overexpression increased HNF4-a
mRNA and protein in TNF-a–treated HepG2 cells to the
levels of untreated HepG2 cells transfected with an EV
(Fig. 2E and F).
TNF-a decreases SHBG production independently
of de novo lipogenesis. To examine whether HNF4A
downregulation observed in HepG2 cells after TNF-a
treatment could be attributed to lipid accumulation (31,32),
we treated HepG2 cells with TNF-a in the presence of
cerulenin, a fatty acid synthase inhibitor (33). Cerulenin
treatment did not block the reduction of SHBG produc-
tion caused by TNF-a in HepG2 cells (Fig. 3A). Moreover,
cerulenin treatment did not block the downregulation of
SHBG and HNF4-a mRNA levels (Fig. 3B) or the re-
duction in HNF4-a protein levels (Fig. 3C). Furthermore,
using oil red staining, we found no evidence of increased
lipid accumulation in HepG2 cells treated with TNF-a
for 5 days when compared with vehicle-treated cells
(Fig. 3D).
Daily TNF-a treatment decreases SHBG production
via NF-kB in human SHBG transgenic mice. To mimic
the situation of chronic low-grade inflammation, we per-
formed an experiment in which mice were treated daily
with an injection of 5 mg i.p. of TNF-a for 5 days. Blood
samples were collected immediately before treatment and
at days 3 and 5 of treatment. The results indicated that
plasma SHBG levels were reduced after days 3 and 5 of
TNF-a treatment, whereas no changes in SHBG levels
were observed in the vehicle-treated mice (Fig. 4A). In
addition, SHBG and HNF4-a mRNA levels (Fig. 4B) and
HNF4-a protein levels (Fig. 4C) were significantly reduced
in the livers of TNF-a–treated mice. Moreover, TNF-a–
treated mice had NF-kB activation in their livers because
there was a significant increase in P-p65 levels when
compared with the vehicle-treated mice (Fig. 4C). ChIP
assays using DNA/protein complexes extracted from the
livers of mice treated with TNF-a or vehicle revealed that
in TNF-a–treated mice, there was a reduction of HNF4-a
binding in the SHBG proximal promoter when compared
with vehicle-treated mice (Fig. 4D).
We next measured the sTNF-a-R1 levels in the blood of
untreated and TNF-a–treated mice. The results showed
that daily TNF-a treatment produced a significant increase
in TNF-a-R1 levels at days 3 and 5 when compared with
the vehicle-treated mice (Fig. 4E). It should be noted that
at day 5, TNF-a-R1 levels of mice treated with TNF-a
(1138 6 47) were almost double the levels of vehicle-
treated mice (700 6 50).
To investigate whether the effect of TNF-a on SHBG was
via NF-kB in our in vivo system, human SHBG transgenic
TABLE 1
Main clinical and biochemical features of type 2 diabetic patients
of the prospective study
Baseline Day 7–10 P*
BMI (kg/m2) 29.8 6 7.3 29.0 6 7.5 NS
Plasma glucose (mmol/L) 10.8 6 3.5 7.7 6 3.9 0.045
Fructosamine 418.5 6 89.2 358.6 6 67.7 0.017
HbA1c (%) 9.9 6 1.8 9.4 6 1.2 0.043
Total cholesterol (mg/dL) 199 6 59 187 6 48 NS
Triglycerides (mg/dL) 203 [69–398] 174 [68–295] 0.021
sTNF-a-R1 (ng/mL) 1.46 6 0.96 0.88 6 0.77 0.003
SHBG (pmol/mL)** 29.8 [5.3–70.6] 37 [12.8–66.8] 0.039
Data are mean 6 SD or median [range]. *Between subjects at the
beginning (baseline) and the end of the insulin treatment (day 7–10).
**SHBG normal levels of males 39.7 6 12.8 and females 55.9 6 12.5.
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FIG. 2. TNF-a influences hepatic SHBG production indirectly by decreasing HNF4-a levels through activation of NF-kB in HepG2 cells. A: Western
blot of HNF4-a and PPIA in total cell protein extracts of HepG2 cells treated with vehicle, insulin, TNF-a, or TNF-a plus insulin for 5 days. B: HepG2
cells were treated daily with vehicle, TNF-a, SP600125, SP600125 plus TNF-a, SB203580, or SB203580 plus TNF-a. SHBG accumulation in the
medium was measured using an ELISA. C: Western blot of HNF4-a and PPIA in total cell protein extracts of HepG2 cells treated as in (B). D: HepG2
cells stably transfected with an EV or an HNF4-a expression vector were daily treated with vehicle or TNF-a (50 ng/mL). SHBG accumulation in the
medium was measured using an ELISA. E: Analysis of SHBG and HNF-4a mRNA levels in HepG2 cells treated as in (D). Human 18S mRNA was
amplified as a control. Data points are shown as mean6 SD of triplicates. F: Western blot of HNF4-a and PPIA in total cell protein extracts of HepG2
cells treated as in (D). *P < 0.05 and **P < 0.01 compared with the control.
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mice were treated with daily intraperitoneal injections of
TNF-a (5 mg) or TNF-a (5 mg) plus the NF-kB inhibitor
QNZ (1 mg) for 5 days. Blood samples were collected im-
mediately before treatment and at days 3 and 5. The results
indicated that plasma SHBG levels were reduced after 5
days of treatment with TNF-a and that cotreatment with
QNZ was able to block the reduction in plasma SHBG levels
caused by TNF-a (Fig. 5A). The QNZ cotreatment also was
FIG. 3. TNF-a did not reduce SHBG production by increasing in de novo lipogenesis in HepG2 cells. A: Cerulenin, an inhibitor of the fatty acid
synthase, did not block the reduction of SHBG production caused by TNF-a in HepG2 cells measured by ELISA. B: Cerulenin treatment also did not
block the reduction of SHBG or HNF4-a mRNA levels caused by the TNF-a treatment. C: Cerulenin treatment also did not block the reduction of
HNF4-a protein levels caused by the TNF-a treatment. D: Daily treatment with TNF-a (50 ng/mL) produces no lipid accumulation in HepG2 cells
when compared with vehicle-treated cells. After treatments, HepG2 cells were washed with PBS twice and formalin fixed for 5 min. After several
washes, the cells were stained with fresh Oil Red O for 15 min and then rinsed in water. **P < 0.01 compared with the control. (A high-quality
digital representation of this figure is available in the online issue.)
R. SIMÓ AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 61, FEBRUARY 2012 377
able to block the downregulation of SHBG and HNF4-a
mRNA levels (Fig. 5B) and the reduction of HNF4-a pro-
tein levels (Fig. 5C).
We did not find hepatic fatty acid accumulation in the
livers of mice treated with TNF-a (Supplementary Fig. 3).
Furthermore, no evidence of liver apoptosis in TNF-a–
treated mice was detected when analyzed by transferase-
mediated dUTP nick-end labeling assay (data not shown).
These findings exclude the possibility that the reduction of
plasma SHBG levels after TNF-a treatment could be at-
tributed to liver damage.
TNF-a-R1, but not insulin, is independently related to
plasma SHBG levels in obese patients. To explore
whether TNF-a is a major factor accounting for the low
levels of SHBG detected in obesity, we measured serum
TNF-a-R1, a well-established surrogate of TNF-a activa-
tion, in 97 consecutive obese subjects (see the inclusion







FIG. 4. Daily treatment with TNF-a reduces plasma SHBG levels in human SHBG transgenic mice. A: Human SHBG transgenic mice (n = 3–4) were
treated over 5 days with intraperitoneal injections of PBS or TNF-a (5 mg), and blood SHBG levels were measured by ELISA. The SHBG levels are
expressed as mean6 SD relative to pretreatment levels to compensate for between-animal variability. B: SHBG andHNF4-amRNA abundance was
determined in relation to 18S RNA (mean 6 SD) in liver of mice treated with vehicle (n = 3) and TNF-a (n = 4). C: Liver HNF4-a and P-p65 protein
levels were measured by Western blotting using PPIA as a housekeeping reference protein. Data points are mean 6 SD of triplicate measurements.
D: Plasma TNF-a-R1 levels were measured by ELISA at days 0, 3, and 5 of mice treated with vehicle (n = 3) and TNF-a (n = 4). E: ChIP assays using
DNA/protein complexes extracted from livers of mice treated with TNF-a or vehicle. The TNF-a–treated mice had a reduction of HNF4-a binding in
the SHBG proximal promoter when compared with the vehicle-treated mice [forward (59-CCCGGTACCTCTAGACCTCAGGCCTGTG-39) and reverse
(59-CCCA AGCTTGGCAGGCAGCC TTGCGTGTGG-39) primers designed to amplify a 306–base pair region in the human SHBG promoter]. *P < 0.05
and **P < 0.01 compared with the control. (A high-quality color representation of this figure is available in the online issue.)
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and analytical features of obese subjects included in the
study are shown in Table 2. Although obese patients with
glucose abnormalities were significantly older (P = 0.018),
and had higher HOMA-IR (P = 0.006) than patients without
glucose abnormalities, plasma SHBG levels were similar
between groups (Table 2). In this cohort of obese subjects,
we found no differences in SHBG levels between men and
women, and for this reason, the results are presented to-
gether. Nevertheless, results according to sex are also
displayed in Fig. 6.
In the univariate analysis, plasma SHBG was inversely
correlated with plasma sTNF-a-R1 (r = 20.546; P , 0.001)
(Fig. 6A). However, no correlation between SHBG and
insulin (r = 20.140; P = 0.199) or HOMA-IR (r = 20.110;
P = 0.314) was observed. In the multiple regression anal-
ysis, sTNF-a-R1 was the only variable that was inde-
pendently related to plasma SHBG levels and explained
the 29.8% of SHBG variation. When a separate analysis was
performed according to the presence or absence of IFG,
the results were very similar (data not shown).
FIG. 5. Daily treatment with QNZ blocked the TNF-a–induced reduction of plasma SHBG levels in human SHBG transgenic mice. A: Human SHBG
transgenic mice (n = 3) were treated over 5 days with intraperitoneal injections of vehicle, TNF-a (5 mg), or TNF-a (5 mg) plus QNZ (1 mg). Blood
SHBG levels were measured by ELISA. The SHBG levels are expressed as mean 6 SD relative to pretreatment levels to compensate for between-
animal variability. B: SHBG and HNF4-a mRNA abundance was determined in relation to 18S RNA (mean 6 SD) in liver of mice treated with
vehicle (n = 3), TNF-a (n = 3), and TNF-a plus QNZ (n = 3). C: Liver HNF4-a protein levels were measured by Western blotting using PPIA as
a housekeeping reference protein. Data points are mean 6 SD of triplicate measurements. **P < 0.01 compared with the control.
TABLE 2
Main clinical and biochemical features of obese patients of the cross-sectional study
Subjects
P*Total With IFG Without glucose abnormalities
n 97 54 43 —
BMI (kg/m2) 44.9 6 6.3 45.3 6 5.9 44.3 6 6.4 0.495
Sex (M/F) 35/62 19/37 18/25 0.196
Age (years) 47.1 6 9.8 50.9 6 8.5 45.5 6 9.7 0.018
Fasting glucose (mmol/L) 5.6 6 1.1 6.1 6 0.4 5.3 6 0.4 ,0.001
Fasting insulin (pmol/L) 21.8 6 12.9 24.7 6 14.3 20.5 6 9.6 0.118
HOMA-IR 5.2 [0.9–23.4] 6.5 [1.5–23.4] 4.8 [0.9–9.9] 0.006
sTNF-a-R1 (ng/mL) 2.4 [1.1–4.1] 2.4 [1.2–3.5] 2.4 [1.1–4.1] 0.959
SHBG (pmol/mL)** 29.5 [8.0–120.5] 28.8 [9.3–115.6] 30.2 [8.0–120.5] 0.635
Data are mean 6 SD or median [range]. *Between subjects with IFG and subjects without glucose abnormalities. **SHBG normal levels of
males 39.7 6 12.8 and females 55.9 6 12.5.
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DISCUSSION
Low plasma levels of SHBG are associated with obesity
and are a risk factor for the development of both type 2
diabetes and cardiovascular disease (2–5). The low plasma
SHBG levels found in obesity have been largely attributed
to hyperinsulinemia, even though there is no obvious
mechanism to account for this (9). Recently, we have
presented evidence that casts doubt on this widely held
assumption and have shown that excessive exposure to
glucose or fructose downregulates SHBG expression in
the liver both in vivo and in vitro by reducing HNF4A
expression (11). In the current study, we have found that
daily treatment with TNF-a reduces SHBG production in
HepG2 cells independently of the presence or absence of
FIG. 6. Negative correlation between plasma SHBG levels and sTNF-a-R1 in the whole population of obese subjects included in the study (A), as
well as according to sex (B and C).
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insulin. Moreover, only cells treated with TNF-a have re-
duced levels of SHBG mRNA when compared with the
cells treated with vehicle or insulin alone. In the clinical
setting, we have demonstrated that TNF-a-R1, but not in-
sulin, is independently related to circulating SHBG in
obese subjects. In addition, we have shown a significant
increase rather than decrease in SHBG plasma levels after
initiating insulin treatment in type 2 diabetic patients.
Taken together, these data strongly argue against the hy-
pothesis that hyperinsulinemia is responsible for the de-
cline in SHBG levels in humans and point to TNF-a as
a key factor accounting for the low plasma levels of SHBG
that exist in low-grade chronic inflammatory diseases
characterized by high levels of TNF-a, such as obesity and
type 2 diabetes.
We have recently found that the human SHBG gene in
HepG2 cells, as well as in a transgenic mouse model,
responds to thyroid hormones (34). Of import, because the
human SHBG promoter lacks a thyroid hormone response
element, these studies demonstrate that the thyroid hormone
effects are mediated by alterations in cellular HNF4-a levels,
which act as a key regulator of SHBG transcription (12). We
therefore explored the possibility that the decrease in SHBG
production in HepG2 cells after 5 days of treatment with
TNF-a involves changes in hepatic HNF4-a levels. In this
regard, it has been previously reported that TNF-a appears
to inhibit HNF4A gene expression (35) and that TNF-a,
through NF-kB, inhibits HNF4A transcriptional activity (36).
Our results support this because we observed a decrease in
cellular HNF4-a protein levels in concert with a decrease in
SHBG production in the cells treated with TNF-a.
Because obese patients have chronic high levels of TNF-a
(18), we treated the mice daily with intraperitoneal injection
of TNF-a over 5 days, and we found clear reductions in both
HNF4-a mRNA and protein levels in the liver, as well as in
plasma SHBG levels. These TNF-a effects were mediated by
NF-kB because it was phosphorylated in the livers of mice
treated with TNF-a, and these effects were blocked by
cotreatment of QNZ. Obesity is a state of chronic low-grade
inflammation, and the high levels of TNF-a derived from
visceral adipose tissue play an essential role in this process
(21,37,38). Therefore, our findings provide the mechanism
by which TNF-a could lead to low plasma levels of SHBG in
obese patients. It should be emphasized that TNF-a-R1
levels at day 5 of the mice treated with TNF-a were almost
double the levels of vehicle-treated mice, thus providing
evidence of activation of the TNF-a system. It is interesting
that a similar increase of circulating TNF-a-R1 levels has
been reported in obese patients with IFG when compared
with lean controls (39). These findings suggest that the
results obtained in our experimental model could be
transferred to the events that are taking place in humans
and not only point to TNF-a as a crucial suppressor of
SHBG expression but also open up a new mechanism
linking obesity with the deleterious consequences arising
from lower levels of SHBG/sex steroids.
It could be argued that the downregulation of SHBG was
due to hepatotoxicity or fatty liver disease mediated by
TNF-a. However, we found neither steatosis nor apoptosis
in the livers of SHBG transgenic mice treated with TNF-a
for 5 days. Moreover, daily treatment with TNF-a did not
produce any lipid accumulation in HepG2 cells when
compared with vehicle-treated cells. Furthermore, after
blocking de novo lipogenesis by using cerulenin (an inhib-
itor of the fatty acid synthase), the reduction in SHBG pro-
duction by TNF-a was unaffected. These findings suggest
that fatty liver disease is not the primary event in the
downregulation of SHBGmediated by TNF-a. Nevertheless,
our results do not deny the possibility that when fatty liver
disease is also present, the downregulation of SHBG could
be accelerated. In this regard, we have previously described
the role of de novo lipogenesis in the downregulation of
hepatic SHBG expression (11), and a strong association
between fatty liver disease and low circulating SHBG levels
has been recently reported (13).
Apart from obesity and type 2 diabetes, there are other
chronic inflammatory diseases, such as rheumatoid ar-
thritis and osteoarthritis, in which both TNF-a activation
and low SHBG levels have been reported (19,20). In ad-
dition, it has been shown that TNF-a blockade in patients
with rheumatoid arthritis (40) and psoriatic arthritis (41)
leads to an increase in blood levels of SHBG. Therefore,
plasma SHBG levels could serve as a biomarker for dis-
eases with chronic inflammation and be an indicator of
a good response to treatment aimed at decreasing TNF-a
levels or blocking TNF-a actions. Finally, our results point
to the downregulation of SHBG mediated by an increase of
TNF-a as one explanation for the low levels of total sexual
steroids that exist in chronic inflammatory diseases such
as obesity and type 2 diabetes (42).
In conclusion, our studies suggest that insulin is not
a suppressor of SHBG production. By contrast, TNF-a
plays an essential role in the downregulation of SHBG
production by decreasing hepatic production of HNF4-a
through NF-kB activation. In addition, we provide evi-
dence that TNF-a is essential in accounting for the low
levels of SHBG detected in obesity.
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